- Home
- NXTC vs PIII Comparison
NXTC vs PIII Comparison
Compare NXTC & PIII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- PIII
- Stock Information
- Founded
- NXTC 2015
- PIII 2015
- Country
- NXTC United States
- PIII United States
- Employees
- NXTC N/A
- PIII N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- PIII Medical/Nursing Services
- Sector
- NXTC Health Care
- PIII Health Care
- Exchange
- NXTC Nasdaq
- PIII Nasdaq
- Market Cap
- NXTC 24.6M
- PIII 28.9M
- IPO Year
- NXTC 2019
- PIII N/A
- Fundamental
- Price
- NXTC $8.71
- PIII $7.50
- Analyst Decision
- NXTC Strong Buy
- PIII Strong Buy
- Analyst Count
- NXTC 3
- PIII 3
- Target Price
- NXTC $23.00
- PIII $17.50
- AVG Volume (30 Days)
- NXTC 85.8K
- PIII 2.3K
- Earning Date
- NXTC 11-05-2025
- PIII 11-14-2025
- Dividend Yield
- NXTC N/A
- PIII N/A
- EPS Growth
- NXTC N/A
- PIII N/A
- EPS
- NXTC N/A
- PIII N/A
- Revenue
- NXTC N/A
- PIII $1,461,823,000.00
- Revenue This Year
- NXTC N/A
- PIII N/A
- Revenue Next Year
- NXTC N/A
- PIII $10.45
- P/E Ratio
- NXTC N/A
- PIII N/A
- Revenue Growth
- NXTC N/A
- PIII 4.20
- 52 Week Low
- NXTC $2.69
- PIII $5.80
- 52 Week High
- NXTC $19.20
- PIII $21.00
- Technical
- Relative Strength Index (RSI)
- NXTC 46.50
- PIII 33.02
- Support Level
- NXTC $8.51
- PIII $7.51
- Resistance Level
- NXTC $10.56
- PIII $8.75
- Average True Range (ATR)
- NXTC 1.23
- PIII 0.29
- MACD
- NXTC -0.36
- PIII -0.15
- Stochastic Oscillator
- NXTC 1.93
- PIII 11.57
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.